Fenfluramine Attenuates Retinal Microglial Activation but Does Not Rescue Structural and Vascular Deficits in a Rat Model of Dravet Syndrome
International Journal of Molecular Sciences · 25.06.2026 · 27 (13) · 5752
DOI: 10.3390/ijms27135752 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.06.2026. Verfasst von Yajuan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China. Hauptthemen laut MEDLINE: Microglia, Retina, Fenfluramine, Epilepsies, Myoclonic. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Major Project, People's Government of Guangdong Province, Brain Science and Brain-like Intelligence Technology.
Abstract (Originalsprache)
Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy caused by SCN1A haploinsufficiency. While brain pathology has been extensively studied, the retina remains underexplored. This study investigated retinal structural, functional, vascular, and cellular changes in a Scn1a+/− rat model of DS. Anatomical quantification revealed thinning of the retinal nerve fiber layer and thickening of the outer plexiform layer. Electroretinography (ERG) showed selectively reduced oscillatory potential amplitudes, suggesting dysfunction of neurovascular coupling. Consistent with these findings, immunohistochemistry demonstrated aberrant vascular morphology, including increased vessel curvature and reduced branching density. In addition, we observed robust microglial activation in the outer and inner plexiform layers; however, astrocyte morphology remained largely unchanged. Fenfluramine, an approved anti-seizure drug for DS, attenuated microglial activation but failed to rescue retinal structural or vascular deficits, indicating a dissociation between its anti-inflammatory and disease-modifying effects. Our findings suggest that multimodal retinal assessment could serve as a noninvasive biomarker platform for monitoring disease progression and therapeutic response in DS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China.
- The Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 1068 Xueyuan Blvd, Shenzhen 230027, China.
- Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 518055, China.
- Department of Pathology and Pathophysiology, Faculty of Basic Medical Sciences, Kunming Medical University, Kunming 650500, China.
ORCID-Profile: Yajuan Zhang, Weixin Qian, Zhonghua Lu
Förderung
- National Science and Technology Major Project
- People's Government of Guangdong Province
- Brain Science and Brain-like Intelligence Technology
- Guangdong Foreign Talents Program
Zitieren
APA
Zhang, Y., Qian, W., Li, M., Zou, Y. Y., Lu, Z., Huang, Z., Naumann, R. K., & Wang, H. (2026). Fenfluramine Attenuates Retinal Microglial Activation but Does Not Rescue Structural and Vascular Deficits in a Rat Model of Dravet Syndrome. International Journal of Molecular Sciences, 27(13), 5752. https://doi.org/10.3390/ijms27135752
Vancouver
Zhang Y, Qian W, Li M, Zou YY, Lu Z, Huang Z, et al. Fenfluramine Attenuates Retinal Microglial Activation but Does Not Rescue Structural and Vascular Deficits in a Rat Model of Dravet Syndrome. International Journal of Molecular Sciences. 2026;27(13):5752. doi:10.3390/ijms27135752
BibTeX
@article{Zhang2026,
author = {Zhang, Yajuan and Qian, Weixin and Li, Miao and Zou, Ying-Ying and Lu, Zhonghua and Huang, Zhihui and Naumann, Robert K and Wang, Hong},
title = {Fenfluramine Attenuates Retinal Microglial Activation but Does Not Rescue Structural and Vascular Deficits in a Rat Model of Dravet Syndrome},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {13},
pages = {5752},
doi = {10.3390/ijms27135752}
}
EUVIMED